Skip to content

SELF-GYN1 (Sonograms Enable Looking Forward- Get Your iNformation 1 Trial)

Sonograms Enable Looking Forward- Get Your iNformation 1 Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05443698
Acronym
SELF-GYN1
Enrollment
365
Registered
2022-07-05
Start date
2022-07-25
Completion date
2023-07-14
Last updated
2023-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fertility Risk

Brief summary

This clinical trial will evaluate the efficacy and safety of the use of the Turtle Health Ultrasound Scanner for the acquisition of transvaginal ultrasound images by a study participant, with no previous training, in her home when guided by real-time remote supervision from a qualified and specially trained ultrasound technologist.

Detailed description

Those images will be assessed for their image quality by qualified Independent Readers. The study is intended to assess the ability of at home imaging performed with the Turtle Health Ultrasound Scanner to reliably produce quality images as compared to objective performance criteria set by the American Institute of Ultrasound in Medicine (AIUM). The clinical investigation is intended to extend the findings of a published trial (SELF-HELP) to real-world performance. Each participant will have imaging performed at-home. The at-home imaging will be conducted using the Turtle Health Ultrasound Scanner, manipulated by the participant and guided in real time by a remote ultrasound technologist that has received special training with the device. Home imaging will follow the procedures included in planned device labeling. Imaging obtained will include, at minimum, each of the specific imaging views and components defined in the American Institute of Ultrasound in Medicine (AIUM) Case Study Submission Requirements: Gynecologic Ultrasound. Imaging Scans will be assessed by at least two (2) independent readers who are physicians expert in the interpretation of transvaginal ultrasound gynecologic imaging studies. Images will have participant name redacted and each independent reader will be blinded to any participant information other than the images themselves. They will also be blinded to the assessments of the other readers. In-clinic Imaging Scans obtained from either or both of previous trials and in-clinic scans will be included in rating batches for calibration.

Interventions

DEVICETransvaginal ultrasound

Adult women in the U.S. who are eligible for the ultrasound trial on the basis of the inclusion/exclusion criteria will complete an at home transvaginal ultrasound guided by real-time remote supervision from a qualified and specially trained ultrasound technologist.

Sponsors

Turtle Health, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Masking description

Independent Readers reviewing Imaging Exams will be fully blinded to participant health history and exam setting.

Intervention model description

Prospective, interventional, single arm clinical trial

Eligibility

Sex/Gender
FEMALE
Age
22 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Woman, as defined by sex at birth * Age 22 years or older at the time of eligibility screening * Premenopausal * BMI \< 40 kg/m2 * Unlikely to be pregnant during home scan, based on either current intrauterine device (IUD) or other birth control use or recent menstruation, defined as the home scan occurring between day 3 and 10 of the menstrual cycle based on patient self-report * English-speaking and able to follow verbal instructions of the remote ultrasound technologist as determined by the ability to complete the consent process unassisted * Ability to manipulate a 1 lb. weight by hand * Residence in state where a PI holds a valid license to practice medicine * Ability to receive signature delivery of the investigational ultrasound device * Ability to return the investigational ultrasound device by specified instructions

Exclusion criteria

* Pregnant or may be pregnant * Has recently given birth, and has had fewer than 3 postpartum menstrual cycles * Has recently had a stillbirth or abortion more than 20 weeks (subject to the 3 postpartum menstrual cycles above). Miscarriages or abortions less than 20 weeks are subject to two wait cycles * Has changed birth control within the current menstrual cycle (one 'washout' cycle is required) * Turtle Health employees * Has known cancer of a pelvic organ, not currently in remission * Not able to schedule a scan while meeting the requirements above prior to the end of the trial. For example, women who change birth control within the last cycle of the trial (and would require a 'washout cycle' that would delay trial close) or who are unable to schedule within the last few weeks of the trial after reasonable scheduling efforts have been made * Previous hysterectomy or oophorectomy * Does not have one or more of the following anatomic organs: vagina, left ovary, right ovary, or uterus * Subjects with prior scanning experience are included in the trial (as they would be in the real world) but excluded from the primary image quality endpoint (due to experience potentially influencing that endpoint) and analyzed separately as a subgroup for that endpoint only. This sub-population is capped at 200 subjects (\ 20% of trial)

Design outcomes

Primary

MeasureTime frameDescription
Image Quality6 weeksEach Independent Reader will make a determination of whether each Imaging Scan is of 'diagnostic quality' or 'not diagnostic quality', in its totality, for the purpose of a diagnostic gynecological ultrasound examination.
Net Promoter Score (NPS)6 weeksAll subjects will be asked to complete the question 'How likely are you to recommend the experience to a friend or colleague?.' It is expected that a high share of patients will report a positive NPS.

Secondary

MeasureTime frameDescription
Box Opening6 weeksPatient opens box at correct time (not early)
Patient Identifier6 weeksCorrect patient is identified by tech and tests (not wrong patient)
Probe Cover6 weeksPatient correctly applies probe cover and uses it successfully during the scan
Correct Cavity6 weeksPatient places probe in correct cavity (vaginal vs. anal)
Timely Return6 weeksPatient ships product back in a timely fashion
Shipping Damage6 weeksRate at which probe is damaged in transit
Successful Return6 weeksRate at which probe remains in working condition and able to be reprocessed
Minor Pain or Discomfort6 weeksRate at which subjects report minor pain, discomfort, or similarly mild symptoms lasting under 24 hours
False Positives6 weeksRate of false positives of 'significant findings'
Successful Reprocessing6 weeksNumber of probes undergoing reprocessing that are reprocessed properly per internal standard operating procedures
Ultrasound technologist satisfaction6 monthsDifference in average weekly satisfaction between in-person and virtual settings based on survey responses
Ultrasound technologist availability6 monthsEstimation of weekly increase in personnel capacity enabled by device based on number of ultrasound technologists available.
Ultrasound technologist safety6 monthsImplied/potential estimation of injury reduction based on survey results
Correct setting of care guess rate6 monthsIncluding in-clinic 'control' data from previous study or from in-clinic scans with same device
Sub-group exploratory endpoints: Endpoint 11 yearResults from the primary end point Image Quality will also be reported by sub-populations of interest. The sub-populations are: 1. Class I obese patients (BMI between 30 and 35, inclusive) 2. Class II+ obese patients (BMI greater than 35) 3. Aged 40 or older 4. Residing in 'completely rural' or 'mostly rural' counties 5. Symptoms indicating possible pathology (where available) 6. No record of visiting a doctor in the 24 months prior to enrollment (where available) 7. Educational attainment less than some college 8. Identifying as Hispanic or Latino 9. Identifying as * American Indian or Alaska Native * Asian * Black or African American * Native Hawaiian or Other Pacific Islander * White * Multiple identities selected
Sub-group exploratory endpoints: Endpoint 21 yearResults from the primary end point Net Promoter Score (NPS) will also be reported by sub-populations of interest. There sub-populations are: 1. Class I obese patients (BMI between 30 and 35, inclusive) 2. Class II+ obese patients (BMI greater than 35) 3. Aged 40 or older 4. Residing in 'completely rural' or 'mostly rural' counties 5. Symptoms indicating possible pathology (where available) 6. No record of visiting a doctor in the 24 months prior to enrollment (where available) 7. Educational attainment less than some college 8. Identifying as Hispanic or Latino 9. Identifying as * American Indian or Alaska Native * Asian * Black or African American * Native Hawaiian or Other Pacific Islander * White * Multiple identities selected
All Other Adverse Events6 weeksRate at which subjects report adverse events, side effects, or other sequelae other than minor pain, discomfort, or similarly mild symptoms lasting under 24 hours
Performance Task of Independent Readers6 weeksEach Independent Reader will assess the suitability of the Imaging Study for use on each of ten specific imaging tasks defined by the AIUM practice parameters as required for a high quality two-dimensional gynecological ultrasound imaging study.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 8, 2026